Does the latest Alzheimer’s disease drug actually work? When does the FDA call in security? And who’s going to be CEO of Biogen?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Lecanemab, a new Alzheimer’s treatment from partners Biogen and Eisai, succeeded in a pivotal clinical trial, and we explain the surprising development and its sweeping implications. Then, oncologist Mikkael Sekeres joins us to talk about his new book, which is a history of the FDA and an insider’s look at one of the agency’s most contentious drug approval hearings.
Post-pandemic, resilience is top of mind for the biopharma industry
Learning through a global pandemic, biopharma is evolving to embrace innovations that could unlock the next wave of life-saving diagnostics, vaccines, and therapies. Cytiva’s Global Biopharma Resilience Index helps us take stock of the opportunities and challenges — like sourcing talent, collaborating with regulatory bodies, and ensuring a robust supply chain — that lie ahead for the industry, according to biopharma executives and policy makers. Here’s what the industry told us.
No comments